PCV43 EVALUATION OF THE ASSOCIATION BETWEEN HEALTH-RELATED UTILITY AND OBESITY IN HOSPITAL TREATED SUBJECTS  by Currie, CJ et al.
331Abstracts
therapy. Persistence (remaining on therapy at 12 months after
therapy initiation), mean medication possession ratio (MPR)
over 12 months, and adherence (adherent to statin deﬁned as
MPR ≥ 0.8) were assessed. RESULTS: Among the 281,564
patients selected, 159,833 (56.8%) started on atorvastatin,
66,526 (23.6%) on simvastatin, 27,187 (9.7%) on pravastatin,
20,921 (7.4%) on ﬂuvastatin, and 7,097 (2.5%) on lovastatin.
The mean age was 61.3+/-13.2 years and 51% were male. The
persistence at 12 months, mean MPR over 12 months, and
adherence rate for all statins was 52.5%, 68.7%, 52.6%, respec-
tively. The persistence rate at 12 months for patients initiated on
atorvastatin, simvastatin, ﬂuvastatin, pravastatin, and lovastatin
was 54.1%, 53.7%, 49.7%, 44.8%, 41.0%, respectively (p <
0.0001 for all comparisons except for atorvastatin vs. simavas-
tatin). The mean MPR for patients initiated on atorvastatin, 
simvastatin, ﬂuvastatin, pravastatin, and lovastatin was 70.1%,
68.3%, 65.2%, 65.1%, and 62.2%, respectively (p < 0.0001 for
all comparisons except for ﬂuvastatin vs. pravastatin). Adher-
ence for patients initiated atorvastatin, simvastatin, pravastatin,
ﬂuvastatin, and lovastatin was 54.1%, 52.6%, 48.4%, 47.7%,
and 47.2% respectively (p < 0.0001 for all comparisons except
for pravastatin vs. ﬂuvastatin, pravastatin vs. lovastatin, and ﬂu-
vastatin vs. lovastatin). CONCLUSIONS: In general, patients
initiated on atorvastatin are most favorable in terms of persis-
tence, medication possession ratio, and adherence rates, followed
by simvastatin, ﬂuvastatin, pravastatin, and lovastatin patients.
While there are statistical signiﬁcant differences between the
agents, additional studies are needed to determine if this trans-
lates to clinical differences.
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OBJECTIVES: The preferred generic measure of health beneﬁt
in economic models is health-related utility. Utility provides a
single measure of health-preference and has interval properties.
A number of treatments are now available to treat obesity. The
purpose of this study was to characterise the relationship
between health utility and obesity as measured by body mass
index (BMI). METHODS: Data were extracted from the Health
Outcomes Data Repository (HODaR), which includes medical
histories (almost no exclusion criteria), biochemistry, health-
related utility (EQ5D), risk factors (including height and weight)
and demographic data on a large number of individuals. The
data used here (n = 18,223) were from hospital inpatients and
outpatients. Univariate analysis was conducted for speciﬁc sub-
groups and risk factors, as well as multivariate modelling.
RESULTS: The general pattern was non-linear (rotated J-shaped
curve). Naturally, there was wide variability but deﬁnite under-
lying structure to the relationship. People had highest utility
when BM I = 20kg·m-2. Below this, utility decreases rapidly.
There was a quadratic decrease in utility from BMI = 25kg·m-2
to BMI = 35kg·m-2 at a rate of 0.0133 utility units per unit BMI
between BMI = 29kg·m-2 to 30kg·m-2, increasing to 0.0325
between BMI = 34kg·m-2 and 35kg·m-2. This rate of deteriora-
tion was consistent for a range of sub-group analyses: age, sex,
employment status and by broad disease categories, the general
association remaining the same, only the intercept varying.
CONCLUSIONS: Health-related utility is a function of obesity.
These data characterise this relationship for the ﬁrst time, and
in a large group of subjects. The pattern of this association was
consistent in all subgroups investigated, and suggests that much
health beneﬁt can be achieved by reducing obesity in the general
population.
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OBJECTIVE: QOL is an important outcome in the evaluation
of weight loss interventions (e.g., drug therapy). The objective of
this study was to determine whether there are country-speciﬁc
differences in the perception of the impact of weight on quality
of life (QOL) or comfort with food. METHODS: The Impact of
Weight on Quality of Life Scale (IWQOL) was administered to
a sample of 2144 obese individuals [Mean body mass index
(BMI) =31.3, 63% > = 1 self-reported comorbidity, mean age =
41 years, 58% female] in Germany (n = 542), Italy (n = 503),
United Kingdom (UK) (n = 539), and United States (n = 560).
The IWQOL consists of 74 items forming 8 subscales: Health,
Social/Interpersonal, Sexual Life, Work, Self-Esteem, Mobility,
Activities of Daily Living, and Comfort with Food. For each
country, Pearson correlations were calculated between demo-
graphics and IWQOL scores. To control for demographic 
differences in country-speciﬁc samples, differences in IWQOL
scores were tested using analysis of covariance controlling for
BMI, total number of self-reported comorbidities, gender, 
and age. RESULTS: Correlations between demographics and
IWQOL subscales across countries followed a similar pattern,
but the correlation coefﬁcients calculated for Germany between
most IWQOL subscale scores and BMI or total comorbidities
were signiﬁcantly (p < 0.05) higher. Signiﬁcant (p < 0.05) country
differences were found for all IWQOL scales. Pairwise compar-
isons showed, for example, that, compared to the other three
countries, the UK sample had signiﬁcantly better Esteem and
Mobility scores; Germany had signiﬁcantly worse Social/Inter-
personal scores; and Italy had signiﬁcantly less comfort with
food (all p < 0.05). CONCLUSIONS: Differences in the per-
ceived impact of weight on QOL found in this study suggest the
need for more research investigating cultural differences in the
perception of obesity. Such differences may impact the inter-
pretation of patient-reported outcome scores obtained in 
international evaluations of obesity interventions.
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